Skip to main content

Snail Antibody - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-29626

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human, Mouse, Primate

Cited:

Mouse

Predicted:

Feline (100%), Hamster (100%), Mustelid (100%), Rat (100%). Backed by our 100% Guarantee.

Applications

Validated:

Western Blot

Cited:

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Format

BSA Free

Concentration

1.0 mg/ml

Product Specifications

Immunogen

Synthetic peptide made to an internal portion of human SNAIL protein (between residues 200-300) [UniProt O95863]

Reactivity Notes

Predicted to react with rat, mink, feline and hamster based on 100% sequence homology.

Localization

Nuclear

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Scientific Data Images for Snail Antibody - BSA Free

Western Blot: Snail AntibodyBSA Free [NBP2-29626]

Western Blot: Snail AntibodyBSA Free [NBP2-29626]

Western Blot: SNAIL Antibody [NBP2-29626] - Western blot analysis of SNAIL in HeLa whole cell extract.
Snail Antibody - BSA Free

Western Blot: Snail Antibody - BSA Free [NBP2-29626] -

microRNA‐196a (miR‐196a) effects are mediated by the NF kappaB signaling pathway. (A) Pathway enrichment meta‐analysis of miRTarBase predicted targets for miR‐196a. (B) Gene expression of the miR‐196a validated target NFKBIA in control and OE33 miR‐196a overexpressing clones. (C) Activity of the NF kappaB pathway in control and OE33 miR‐196a clones. Cells were transfected with a plasmid containing 4xNF kappaB response elements controlling the expression of the downstream luciferase gene. After 48 h, protein extract was obtained and luciferase activity was quantified using the Dual‐Glo Luciferase Assay System. (D) Reversion of the mesenchymal phenotype of control and OE33 miR‐196a overexpressing clones after inhibition of NF kappaB. Cells were treated with 10 μm of NAI or DMSO as control for 18 h. Scale bar, 100 μm. (E) Western Blot images showing the inhibition of the increase in both SNAIL1 and VIMENTIN protein levels, and in cell motility (F) of control and OE33 miR‐196a overexpressing clones after inhibition of NF kappaB signaling using 10 μm of NAI or DMSO as control for 18 h. Data are mean + standard error of the mean of three independent experiments. **P < 0.01 and ***P < 0.001 for analysis of variance (ANOVA), plus Bonferroni post‐test. ns, not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40955778), licensed under a CC-BY license. Not internally tested by Novus Biologicals.
Snail Antibody - BSA Free

Western Blot: Snail Antibody - BSA Free [NBP2-29626] -

microRNA‐196a (miR‐196a) effects are mediated by TERT. (A–D) TERT siRNA interference reduces the expression of epithelial‐to‐mesenchymal transition markers (EMT) in miR‐196a overexpressing OE33 clones both at mRNA and protein levels. Cells were transfected using Lipofectamine 2000 with TERT siRNA or control siRNA (ctrl siRNA) and gene expression was analyzed after 48 h by qPCR (A–C). Protein expression in these cells was analyzed by western blot (D). (E–G) Reduction of miR‐196a‐mediated increase in the expression of EMT markers, both at mRNA and protein levels, upon TERT inhibition. Control cells and OE33 clones overexpressing miR‐196a were treated with 20 μm of BIBR1532 or DMSO as control for 18 h, and gene and protein expression were analyzed. (H) Reduction of miR‐196a‐mediated increase in cell motility upon TERT inhibition. Control cells and OE33 clones overexpressing miR‐196a were treated with 20 μm of BIBR1532 or DMSO as control for 18 h, and cell motility was analyzed by wound‐healing assay. Data are mean + standard error of the mean of three independent experiments. **P < 0.01 and ***P < 0.001 for analysis of variance (ANOVA), plus Bonferroni post‐test. ns, not significant. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/40955778), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for Snail Antibody - BSA Free

Application
Recommended Usage

Western Blot

1.0 ug/ml

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: Snail

Snail, also called SNAIL1 or SNAI1, is a zinc-finger transcription factor belonging to the Snail superfamily and encoded by the SNAI1 gene (1,2). Snail was first discovered in Drosophila and has homologs in many species including vertebrates and humans (1,2). The Snail family members includes Snail (Snail1), Slug (Snail2), and Smuc (Snail3) (1,2). In humans, Snail is expressed in a number of tissues including placenta, brain, and skeletal muscle, but is most highly expressed by the kidneys (1). Snail functions in repression of E-cadherin transcription which is associated with epithelial-mesenchymal transition (EMT) that is especially prominent during embryonic development (1-5). Along with Snail, other related EMT-inducing transcription factors (EMT-TFs) include the Twist and ZEB protein families (3). Snail is synthesized as a protein of 264 amino acids (aa) with an N-terminal SNAG domain, a serine-rich domain (SRD), nuclear export sequences (NES), and four C-terminal zinc-finger binding domains, with a theoretical molecular weight of 29 kDa (1,3). Snail activity is largely regulated through post-translational modifications such as phosphorylation, ubiquitination, and glycosylation, which impacts Snail's localization and stability, amongst other things (1-3, 5).

In addition to its role in embryonic development, Snail-induced EMT is also associated with cancer metastasis (1-5). Snail is expressed in a variety of cancer lines including breast cancer, cervical carcinoma, and colorectal carcinoma, and typically results in increased migration, invasion, and metastasis (1). Accordingly, Snail expression is also correlated with drug resistance and tumor recurrence (1-5). Chemical inhibitors that target Snail have shown some promise in reducing or eliminating Snail-induced EMT, increasing E-cadherin expression, and increasing tumor regression (1).

1. Kaufhold, S., & Bonavida, B. (2014). Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-014-0062-0

2. Wang, Y., Shi, J., Chai, K., Ying, X., & Zhou, B. P. (2013). The Role of Snail in EMT and Tumorigenesis. Current Cancer Drug Targets. https://doi.org/10.2174/15680096113136660102

3. Kang, E., Seo, J., Yoon, H., & Cho, S. (2021). The Post-Translational Regulation of Epithelial-Mesenchymal Transition-Inducing Transcription Factors in Cancer Metastasis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22073591

4. Seo, J., Ha, J., Kang, E., & Cho, S. (2021). The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance. Archives of Pharmacal Research. https://doi.org/10.1007/s12272-021-01321-x

5. Baulida, J., Diaz, V. M., & Herreros, A. G. (2019). Snail1: A Transcriptional Factor Controlled at Multiple Levels. Journal of Clinical Medicine. https://doi.org/10.3390/jcm8060757

Alternate Names

SLUGH2, SNAH, SNAI1

Entrez Gene IDs

6615 (Human)

Gene Symbol

SNAI1

Additional Snail Products

Product Documents for Snail Antibody - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Snail Antibody - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...